NASDAQ:ZYNE - Zynerba Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.11 -0.43 (-9.46 %) (As of 02/27/2020 02:45 PM ET) Add Compare Today's Range$3.93Now: $4.11▼$4.4850-Day Range$4.49MA: $5.18▼$6.1652-Week Range$4.38Now: $4.11▼$16.47Volume835,161 shsAverage Volume568,672 shsMarket Capitalization$95.43 millionP/E RatioN/ADividend YieldN/ABeta4.59 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZYNE Previous Symbol CUSIPN/A CIK1621443 Webhttp://www.zynerba.com/ Phone484-581-7505Debt Debt-to-Equity RatioN/A Current Ratio10.08 Quick Ratio10.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$90,000.00 Price / Sales1,060.37 Cash FlowN/A Price / Cash FlowN/A Book Value$3.27 per share Price / Book1.26Profitability EPS (Most Recent Fiscal Year)($2.61) Net Income$-39,910,000.00 Net MarginsN/A Return on Equity-40.53% Return on Assets-36.09%Miscellaneous Employees25 Outstanding Shares23,200,000Market Cap$95.43 million Next Earnings Date3/9/2020 (Estimated) OptionableOptionable Receive ZYNE News and Ratings via Email Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ZYNE Rates by TradingView Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions What is Zynerba Pharmaceuticals' stock symbol? Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE." How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) issued its earnings results on Wednesday, November, 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.52) by $0.08. View Zynerba Pharmaceuticals' Earnings History. When is Zynerba Pharmaceuticals' next earnings date? Zynerba Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zynerba Pharmaceuticals. What price target have analysts set for ZYNE? 7 brokerages have issued twelve-month price objectives for Zynerba Pharmaceuticals' stock. Their forecasts range from $11.00 to $26.00. On average, they anticipate Zynerba Pharmaceuticals' stock price to reach $17.83 in the next twelve months. This suggests a possible upside of 333.5% from the stock's current price. View Analyst Price Targets for Zynerba Pharmaceuticals. What is the consensus analysts' recommendation for Zynerba Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynerba Pharmaceuticals. What are Wall Street analysts saying about Zynerba Pharmaceuticals stock? Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock: 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (2/26/2020) 2. LADENBURG THALM/SH SH analysts commented, "We understand the market’s reaction when focusing on a few items: 1) There was a case of status epilepticus (SE); 2) 96% of patients reported an adverse event (AE); 3) 10/48 (21%) reported a serious adverse event (SAE); 4) Zygel doesn’t work fast enough; 5) 7 of 48 (15%) dropped out for efficacy; and 6) There were only 11 Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) patients. However, we find some perspective on these figures are important to consider: 1. SE has not been found in any previous Zygel trial, including the Phase 2s in adult refractory epilepsy (n=188), osteoarthritis of the knee (n=300) and Fragile X syndrome (FXS; n=16). As we have described in our notes on Buy), SE typically occurs in patients highly compromised by underlying health conditions and/or trauma." (9/18/2019) 3. Cantor Fitzgerald analysts commented, "We rate ZYNE Overweight. We focus our valuation on FXS, where we are encouraged by the open-label, long-term data, with meaningful and durable improvements that we see having predictive value for the pbo-controlled pivotal CONNECT-FX trial. On epilepsy indications, we await further data after a disappointment in focal epilepsy. Section may be found on pages 4 – 5.We use a discounted NPV revenue calculation that yields ~$8 for ZYN002 in the U.S. FXS market and ~$3 in the EU." (3/7/2019) Has Zynerba Pharmaceuticals been receiving favorable news coverage? Headlines about ZYNE stock have been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of -3.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Zynerba Pharmaceuticals. Are investors shorting Zynerba Pharmaceuticals? Zynerba Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 6,390,000 shares, an increase of 7.8% from the January 15th total of 5,930,000 shares. Based on an average daily trading volume, of 560,900 shares, the short-interest ratio is presently 11.4 days. Currently, 31.6% of the company's shares are sold short. View Zynerba Pharmaceuticals' Current Options Chain. Who are some of Zynerba Pharmaceuticals' key competitors? Some companies that are related to Zynerba Pharmaceuticals include Aptorum Group (APM), Progenics Pharmaceuticals (PGNX), Kindred Biosciences (KIN), Merus (MRUS), Avedro (AVDR), Mallinckrodt (MNK), Puma Biotechnology (PBYI), OrganiGram (OGI), Mirum Pharmaceuticals (MIRM), Avadel Pharmaceuticals (AVDL), Galera Therapeutics (GRTX), Avid Bioservices (CDMO), Fulcrum Therapeutics (FULC), Xenon Pharmaceuticals (XENE) and Dynavax Technologies (DVAX). What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), Insys Therapeutics (INSY), NVIDIA (NVDA), Alibaba Group (BABA), Innovative Industrial Properties (IIPR) and Advanced Micro Devices (AMD). Who are Zynerba Pharmaceuticals' key executives? Zynerba Pharmaceuticals' management team includes the folowing people: Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 61)Ms. Terri B. Sebree, Pres (Age 61)Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 55)Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 50)Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 62) When did Zynerba Pharmaceuticals IPO? (ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. Who are Zynerba Pharmaceuticals' major shareholders? Zynerba Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.74%), Geode Capital Management LLC (1.20%), AdvisorShares Investments LLC (1.16%), Prentice Capital Management LP (0.90%), Campbell Capital Management Inc. (0.31%) and Bank of New York Mellon Corp (0.29%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Institutional Ownership Trends for Zynerba Pharmaceuticals. Which institutional investors are selling Zynerba Pharmaceuticals stock? ZYNE stock was sold by a variety of institutional investors in the last quarter, including Campbell Capital Management Inc., New York State Common Retirement Fund and Claraphi Advisory Network LLC. View Insider Buying and Selling for Zynerba Pharmaceuticals. Which institutional investors are buying Zynerba Pharmaceuticals stock? ZYNE stock was bought by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, Prentice Capital Management LP, Dynamic Technology Lab Private Ltd, State Street Corp, California Public Employees Retirement System, Cubist Systematic Strategies LLC, AQR Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Insider Buying and Selling for Zynerba Pharmaceuticals. How do I buy shares of Zynerba Pharmaceuticals? Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Zynerba Pharmaceuticals' stock price today? One share of ZYNE stock can currently be purchased for approximately $4.11. How big of a company is Zynerba Pharmaceuticals? Zynerba Pharmaceuticals has a market capitalization of $95.43 million and generates $90,000.00 in revenue each year. The company earns $-39,910,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Zynerba Pharmaceuticals employs 25 workers across the globe.View Additional Information About Zynerba Pharmaceuticals. What is Zynerba Pharmaceuticals' official website? The official website for Zynerba Pharmaceuticals is http://www.zynerba.com/. How can I contact Zynerba Pharmaceuticals? Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected] MarketBeat Community Rating for Zynerba Pharmaceuticals (NASDAQ ZYNE)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 591 (Vote Outperform)Underperform Votes: 518 (Vote Underperform)Total Votes: 1,109MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/27/2020 by MarketBeat.com StaffFeatured Article: Market Perform
